Risk of coronary artery disease in patients with ankylosing spondylitis: A systematic review and meta-analysis

Annals of Translational Medicine

Volumn 3, Issue 4, 2015, Pages

  Ungprasert, Patompong ^a   Srivali, Narat ^a   Kittanamongkolchai, Wonngarm ^a  

^a MAYO CLINIC   (United States)

Author keywords

Ankylosing spondylitis (AS); Epidemiology; Meta analysis; Venous thromboembolism

Indexed keywords

EID: 85015504398     PISSN: 23055839     EISSN: 23055847     Source Type: Journal    
DOI: 10.3978/j.issn.2305-5839.2015.02.05     Document Type: Article

References (40)

1. Frostegård J. Atherosclerosis in patients with autoimmune disorders. Arterioscler Thromb Vasc Biol 2005;25:1776-85.
2. Ait-Oufella H, Sage AP, Mallat Z, et al. Adaptive (T and B cells) immunity and control by dendritic cells in atherosclerosis. Circ Res 2014;114:1640-60.
3. Montecucco F, Mach F. Common inflammatory mediators orchestrate pathophysiological processes in rheumatoid arthritis and atherosclerosis. Rheumatology (Oxford) 2009;48:11-22.
4. Rho YH, Chung CP, Oeser A, et al. Interaction between oxidative stress and high-density lipoprotein cholesterol is associated with severity of coronary artery calcification in rheumatoid arthritis. Arthritis Care Res (Hoboken) 2010;62:1473-80.
5. Niessner A, Sato K, Chaikof EL, et al. Pathogen-sensing plasmacytoid dendritic cells stimulate cytotoxic T-cell function in the atherosclerotic plaque through interferon-alpha. Circulation 2006;114:2482-9.
6. Hänsel S, Lässig G, Pistrosch F, et al. Endothelial dysfunction in young patients with long-term rheumatoid arthritis and low disease activity. Atherosclerosis 2003;170:177-80.
7. Xu J, Lupu F, Esmon CT. Inflammation, innate immunity and blood coagulation. Hamostaseologie 2010;30:5-6, 8-9.
8. Esmon CT. The interactions between inflammation and coagulation. Br J Haematol 2005;131:417-30.
9. Maradit-Kremers H, Nicola PJ, Crowson CS, et al. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 2005;52:722-32.
10. Ungprasert P, Wijarnpreecha K, Ahuja W. Coronary artery disease in primary biliary cirrhosis: a systematic review and meta-analysis of observational studies. Hepatol Res 2014. [Epub ahead of print].
11. Ungprasert P, Charoenpong P, Ratanasrimetha P, et al. Risk of coronary artery disease in patients with systemic sclerosis: a systematic review and meta-analysis. Clin Rheumatol 2014;33:1099-104.
12. Ungprasert P, Suksaranjit P, Spanuchart I, et al. Risk of coronary artery disease in patients with idiopathic inflammatory myopathies: a systematic review and meta-analysis of observational studies. Semin Arthritis Rheum 2014;44:63-7.
13. Ungprasert P, Koster MJ, Warrington KJ. Coronary artery disease in giant cell arteritis: A systematic review and meta-analysis. Semin Arthritis Rheum 2014. [Epub ahead of print].
14. Dean LE, Jones GT, MacDonald AG, et al. Global prevalence of ankylosing spondylitis. Rheumatology (Oxford) 2014;53:650-7.
15. Raychaudhuri SP, Deodhar A. The classification and diagnostic criteria of ankylosing spondylitis. J Autoimmun 2014;48-49:128-33.
16. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010;25:603-5.
17. Herzog R, Álvarez-Pasquin MJ, Díaz C, et al. Are healthcare workers' intentions to vaccinate related to their knowledge, beliefs and attitudes? A systematic review. BMC Public Health 2013;13:154.
18. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88.
19. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
20. Available online: http://www.blackwellpublishing.com/acrmeeting/abstract.asp?MeetingID=799&id=110143
21. Sukenik S, Pras A, Buskila D, et al. Cardiovascular manifestations of ankylosing spondylitis. Clin Rheumatol 1987;6:588-92.
22. Han C, Robinson DW Jr, Hackett MV, et al. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 2006;33:2167-72.
23. Peters MJ, Visman I, Nielen MM, et al. Ankylosing spondylitis: a risk factor for myocardial infarction? Ann Rheum Dis 2010;69:579-81.
24. Berg IJ, Provan S, van der Heijde DMFM, et al. Increased risk of cardiovascular disease in patients with active analysing spondylitis. Presented at the American College of Rheumatology Annual Scientific Meeting, Chicago, Illinois, 2011:abstract 513.
25. Kumar S, Mains T, Majithia V. High prevalence of coronary heart disease and its risk factor in veteran with spondyloarthritides. Presented at the American College of Rheumatology Annual Scientific Meeting, Chicago, Illinois, 2011:abstract 1286.
26. Bremander A, Petersson IF, Bergman S, et al. Population-based estimates of common comorbidities and cardiovascular disease in ankylosing spondylitis. Arthritis Care Res (Hoboken) 2011;63:550-6.
27. Szabo SM, Levy AR, Rao SR, et al. Increased risk of cardiovascular and cerebrovascular diseases in individuals with ankylosing spondylitis: a population-based study. Arthritis Rheum 2011;63:3294-304.
28. Brophy S, Cooksey R, Atkinson M, et al. No increased rate of acute myocardial infarction or stroke among patients with ankylosing spondylitis-a retrospective cohort study using routine data. Semin Arthritis Rheum 2012;42:140-5.
29. Zöller B, Li X, Sundquist J, et al. Risk of subsequent coronary heart disease in patients hospitalized for immune-mediated diseases: a nationwide follow-up study from Sweden. PLoS One 2012;7:e33442.
30. Chou CH, Lin MC, Peng CL, et al. A nationwide population-based retrospective cohort study: increased risk of acute coronary syndrome in patients with ankylosing spondylitis. Scand J Rheumatol 2014;43:132-6.
31. Miller RG. The jackknife: a review. Biometrika 1974;61:1-15.
32. Gordeev VS, Maksymowych WP, Schachna L, et al. Understanding presenteeism in patients with ankylosing spondylitis: contributing factors and association with sick leave. Arthritis Care Res (Hoboken) 2014;66:916-24.
33. Prince DS, McGuigan LE, McGirr EE. Working life and physical activity in ankylosing spondylitis pre and post anti-tumor necrosis factor-alpha therapy. Int J Rheum Dis 2014;17:165-72.
34. Dagfinrud H, Kjeken I, Mowinckel P, et al. Impact of functional impairment in ankylosing spondylitis: impairment, activity limitation, and participation restrictions. J Rheumatol 2005;32:516-23.
35. Mathieu S, Gossec L, Dougados M, et al. Cardiovascular profile in ankylosing spondylitis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 2011;63:557-63.
36. Evans J, Goedecke JH, Söderström I, et al. Depot-and ethnic-specific differences in the relationship between adipose tissue inflammation and insulin sensitivity. Clin Endocrinol (Oxf) 2011;74:51-9.
37. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-102.
38. Ungprasert P, Kittanamongkolchai W, Cheungpasitporn W, et al. What is the "safest" non-steroidal anti-inflammatory drugs. Am Med J 2012;3:115-23.
39. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006;296:1633-44.
40. Ungprasert P, Sanguankeo A, Upala S, et al. Risk of malignancy in patients with giant cell arteritis and polymyalgia rheumatica: a systematic review and meta-analysis. Semin Arthritis Rheum 2014;44:366-70.